Key facts
- It has raised $1.8M across 2 recorded rounds; the latest was Seed Round ($1.1M) in Apr 2026.
- Notable investors include Cedars Sinai Health Ventures.
- Mitera Biosciences has filed 2 Form Ds with the SEC since 2024, most recently Dec 2025 ($1.7M sold to 6 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Mitera Biosciences
Funding rounds
2 roundsAbout Mitera Biosciences
Developer of an investigational therapeutic drug designed to modulate regulatory T cell activity for managing transplant rejection and autoimmune disorders. The company offers a proprietary innate-immune-pathway mechanism licensed from a medical institution, enabling patients with immune-related conditions to access treatment options intended to reduce reliance on conventional immunosuppressants.
- Sector
- Healthcare
- HQ
- Bellevue, WA, United States
- Founded
- 2020
- Website
- miterabio.com/
- Ownership
- Privately Held (backing)
Mitera Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mitera Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mitera Biosciences in its N-PORT filings yet. We sweep new filings monthly.